Gland Pharma Ltd had rallied 8 per cent to Rs 4,087.65 on the Bombay Stock Exchange (BSE) in intra-day trade on Thursday after the company reported strong revenue growth of 31 per cent year-on-year (YoY) at Rs 1,154 crore for the quarter ended June 2021 (Q1FY22). It had posted a revenue of Rs 884 crore in the year-ago quarter.

The stock was trading at its highest level since listing on November 20, 2020. In the past month, it has outperformed Sensex by surging nearly 30 per cent against a 0.44 per cent gain in the index.

• Piramal Finance Q2 Profit Jumps 67% to Rs 545 Cr
• IRDAI plans lower commissions, minor hit for PSU Banks
• SML Mahindra Q2 Sales Rise 20.7% but Profit Falls 44%
• Hindustan Zinc Q2 Profit Jumps 142% to Record Rs 6,412 Cr
• Aeroflex Industries Gets Indian Patent for 3D Hose Design Tool

Gland Pharma said the revenue growth was contributed from a mix of the launch of new products and volume growth in existing products. The key markets are the US, Canada, Europe, and Australia, which registered an increase of 16 per cent and accounted for 61 per cent of its revenue during Q1FY22. This performance is driven by essential products like Micafungin, Enoxaparin, Heparin, Dexmedetomidine, and new product launches.

Stock Covered in the news

Gland Pharma Ltd-View Detailed Analysis